Blue Jet Healthcare: Should You Buy, Hold, or Sell Right Now?
- September 9, 2026
- Posted by: Harsh Piplani
- Category: Market
Blue Jet Healthcare share price Rs 581.60 (NSE), well off its 52-week high. 52-week range Rs 325 to Rs 759.50. Q1 FY27 profit recovered 21.6% QoQ despite a YoY decline against a high base.
Quick Answer
Blue Jet Healthcare Ltd share price is trading around Rs 582, roughly 23 percent below its 52-week high of Rs 759.50 but well above its 52-week low of Rs 325. Q1 FY27 revenue was Rs 293.11 crore, down 17.4 percent year on year against a high base but up a robust 24.9 percent sequentially from Rs 234.67 crore in the preceding quarter, with net profit of Rs 78.26 crore, up 21.6 percent quarter on quarter. Management noted that inventory destocking in the Pharmaceutical Intermediates segment has been completed, improving order visibility, with contrast media expected to deliver double-digit growth in FY27. The stock trades at 46.81 times earnings, roughly in line with the pharmaceutical sector average near 51.2 times.
Blue Jet Healthcare share price has pulled back roughly 23 percent from its 52-week high of Rs 759.50, with Blue Jet Healthcare share price around Rs 582 on the NSE, well above its 52-week low of Rs 325. With a strong sequential recovery in Q1 FY27 following completed inventory destocking, investors are asking whether this pharmaceutical intermediates manufacturer is a stock to buy at the current level, a hold, or a sell.
This Blue Jet Healthcare stock analysis walks through the Q1 FY27 sequential recovery, management’s outlook on the Pharmaceutical Intermediates and Contrast Media segments, valuation against the pharmaceutical sector, shareholding pattern and the technical setup, using figures sourced from public filings and company disclosures.
Click Here – Get Free Investment Predictions
About Blue Jet Healthcare
Before deciding on Blue Jet Healthcare share price, it helps to understand the underlying business. Blue Jet Healthcare Ltd. manufactures pharmaceutical intermediates and contrast media agents, serving global pharmaceutical and diagnostic imaging customers.
As a pharmaceutical intermediates manufacturer, Blue Jet Healthcare’s Q1 FY27 results showed a sequential recovery following completed inventory destocking in its Pharmaceutical Intermediates segment, with management expressing confidence in improved order visibility and the potential to surpass previous peak sales from FY25.
Blue Jet Healthcare Share Price Today: Key Levels
The table below summarises where Blue Jet Healthcare share price stands right now against its recent trading range and market value.
| Metric | Value |
|---|---|
| Blue Jet Healthcare CMP (NSE) | Rs 581.60 |
| Blue Jet Healthcare CMP (BSE) | Rs 581.85 |
| 52-Week High | Rs 759.50 |
| 52-Week Low | Rs 325.00 |
| Market Capitalisation | Approximately Rs 10,996 crore |
| Dividend Yield | 0.19% |
Blue Jet Healthcare share price is trading well above its 52-week low, even as it remains below its 52-week high, reflecting a sequential recovery following the inventory destocking phase.
Check the Univest Screener for Live Stock Data
Blue Jet Healthcare Financial Performance
The Blue Jet Healthcare share price trend is closely tied to how these numbers evolve each quarter. Blue Jet Healthcare reported Q1 FY27 (June 2026 quarter) revenue of Rs 293.11 crore, down 17.4 percent year on year from a high base of Rs 354.76 crore, but up a robust 24.9 percent sequentially from Rs 234.67 crore in the preceding March 2026 quarter. Net profit stood at Rs 78.26 crore, up 21.6 percent quarter on quarter, with profit before tax expanding to Rs 105.95 crore from Rs 87.15 crore in the preceding quarter.
Management specifically noted that inventory destocking in the Pharmaceutical Intermediates segment has been completed, leading to improved order visibility and confidence in surpassing the company’s previous peak sales from FY25, while the Contrast Media business is forecasted to deliver double-digit growth in FY27, supported by volume growth and new product launches.
| Period | Revenue | Net Profit | Comment |
|---|---|---|---|
| Q1 FY27 (Jun 2026) | Rs 293.11 crore | Rs 78.26 crore | Revenue -17.4% YoY vs high base; +24.9% QoQ recovery |
Valuation Check: Is Blue Jet Healthcare Share Price Expensive?
Any view on Blue Jet Healthcare share price should start from these valuation multiples. Blue Jet Healthcare share price currently reflects a price to earnings ratio of about 46.81 times trailing earnings, roughly in line with the broader pharmaceutical sector average of roughly 51.2 times. The price to book ratio stands near 5.1 times, supported by a strong 18.22 percent return on equity.
Debt to equity of 0.03 is very low. Given the sequential recovery and management’s confidence in improved order visibility, this roughly in-line valuation could offer room for re-rating if the recovery continues to build through FY27.
Technical Signals: What the Chart Shows
Price action here often foreshadows the next move in Blue Jet Healthcare share price. Blue Jet Healthcare share price is currently positioned roughly 23 percent below its 52-week high of Rs 759.50 and well above its 52-week low of Rs 325, reflecting a meaningful pullback from its high despite the sequential recovery underway. A stock trading here often reflects the market awaiting further confirmation that the year-on-year decline against the high base has fully reversed.
Trading volumes remain heavy, so investors should track Blue Jet Healthcare share price alongside continued sequential trends in both the Pharmaceutical Intermediates and Contrast Media segments in coming quarters, rather than reading too much into the year-on-year comparison against an unusually strong base at these technical levels.
Download the Univest iOS App or Univest Android App to track Blue Jet Healthcare’s live price and technical levels.
Shareholding Pattern
Shifts here can influence Blue Jet Healthcare share price more than headline news on some sessions. Blue Jet Healthcare is a promoter-led pharmaceutical intermediates and contrast media manufacturer with very low leverage. A detailed current promoter, FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company’s latest exchange filing.
Why Investors Are Watching Blue Jet Healthcare
- Completed inventory destocking with improved order visibility: Management has specifically confirmed that the Pharmaceutical Intermediates segment’s inventory destocking phase is complete, improving order visibility for coming quarters.
- Strong sequential recovery: Q1 FY27 revenue grew 24.9 percent quarter on quarter, with profit up 21.6 percent, showing the recovery from the destocking-affected period is underway.
- Positive Contrast Media segment outlook: Management expects double-digit growth in the Contrast Media business in FY27, supported by volume growth and new iodinated and gadolinium product launches.
- Very low financial leverage: A debt to equity ratio of just 0.03 gives the company significant financial flexibility.
Risks and Factors to Watch
- Year-on-year revenue decline against a high base: Q1 FY27 revenue fell 17.4 percent year on year, and investors should confirm the sequential recovery continues rather than assuming the year-on-year comparison alone tells the full story.
- Pharmaceutical intermediates sector competitive pressure: Blue Jet Healthcare competes against other domestic and international pharmaceutical intermediates and contrast media manufacturers.
- Customer inventory cycle dependence: As demonstrated by the recent destocking phase, the company’s revenue can be affected by customer inventory management cycles beyond its direct control.
- Regulatory and quality compliance risk: As a manufacturer of pharmaceutical intermediates and contrast media, the company faces exposure to stringent regulatory and quality compliance requirements across its served global markets.
Blue Jet Healthcare Share Price Target: What the Data Suggests
Until then, Blue Jet Healthcare share price remains best tracked through live, verified data rather than a single fixed number. Blue Jet Healthcare does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. What the data shows is a company showing a sequential recovery with improved order visibility, trading roughly in line with the pharmaceutical sector.
Investors who want live, updated research can check the Univest Screener, and should consult a SEBI-registered investment adviser for guidance tailored to their own goals.
Blue Jet Healthcare: Should You Buy, Hold, or Sell Right Now?
This is the core question behind Blue Jet Healthcare share price right now. The Blue Jet Healthcare buy or sell decision depends on whether the sequential recovery continues to build.
The case for buying: Investors who believe in Blue Jet Healthcare’s Pharmaceutical Intermediates and Contrast Media businesses, and trust management’s confidence in improved order visibility, may find the current level worth considering.
The case for holding: Existing shareholders who already track Blue Jet Healthcare’s business may prefer to stay invested and monitor continued sequential trends.
The case for waiting: Investors wanting to see the year-on-year decline fully reverse before committing fresh capital may prefer to wait for that confirmation.
Weigh this against your own risk tolerance and consult a SEBI-registered investment adviser if unsure.
Conclusion
Blue Jet Healthcare share price reflects a pharmaceutical intermediates manufacturer showing a strong sequential recovery in Q1 FY27 following completed inventory destocking, even as year-on-year revenue remains down against a high base, trading roughly in line with the pharmaceutical sector well below its 52-week high. This article is for informational purposes and not a personalised investment recommendation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Q1. Is Blue Jet Healthcare a good stock to buy right now?
Ans. Blue Jet Healthcare’s Q1 FY27 revenue grew 24.9 percent sequentially with profit up 21.6 percent quarter on quarter, following completed inventory destocking, though revenue remained down 17.4 percent year on year against a high base. The stock trades roughly in line with the pharmaceutical sector.
Q2. What is the Blue Jet Healthcare share price today?
Ans. Blue Jet Healthcare share price is trading around Rs 582 on the NSE. The stock’s 52-week high is Rs 759.50 and its 52-week low is Rs 325.
Q3. What is the Blue Jet Healthcare share price target?
Ans. Blue Jet Healthcare does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. Investors can check live research on the Univest Screener and consult a SEBI-registered adviser.
Q4. What does Blue Jet Healthcare manufacture?
Ans. Blue Jet Healthcare manufactures pharmaceutical intermediates and contrast media agents, serving global pharmaceutical and diagnostic imaging customers.
Q5. Why did Blue Jet Healthcare’s revenue recover in Q1 FY27?
Ans. Blue Jet Healthcare’s Q1 FY27 revenue grew 24.9 percent sequentially after the company completed inventory destocking in its Pharmaceutical Intermediates segment, improving order visibility going forward.
Q6. What is Blue Jet Healthcare’s market capitalisation and PE ratio?
Ans. Blue Jet Healthcare has a market capitalisation of approximately Rs 10,996 crore and trades at a price to earnings ratio of about 46.81 times, roughly in line with the pharmaceutical sector average PE of roughly 51.2 times.
